DCTH · Insider Trading
Delcath Systems Inc
Every open-market purchase and sale reported by DCTH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-14 | Rosalind Advisors, Inc. | Director | MIXED | −71,625 | — |
| 2026-05-14 | Elizabeth Czerepak | Director | A | +22,500 deriv. | — |
| 2026-05-14 | Gil Aharon | Director | A | +22,500 deriv. | — |
| 2026-05-14 | Steven A J Salamon | Director | A | +22,500 deriv. | — |
| 2026-05-14 | John Richard Sylvester | Director | A | +22,500 deriv. | — |
| 2026-05-14 | Bridget A Martell | Director | A | +22,500 deriv. | — |
| 2026-03-06 | Sandra Pennell | Chief Financial Officer | Buy | +5,533 | +$50.02K |
| 2026-03-03 | Gerard J Michel | CHIEF EXECUTIVE OFFICER | Buy | +11,200 | +$100.31K |
| 2026-02-18 | Vojo Vukovic | CHIEF MEDICAL OFFICER | A | +84,750 deriv. | — |
| 2026-02-18 | David L. Hoffman | GEN'L COUNSEL, CCO & SECY | A | +84,750 deriv. | — |
| 2026-02-18 | Gerard J Michel | CHIEF EXECUTIVE OFFICER | A | +292,500 deriv. | — |
| 2026-02-18 | Sandra Pennell | Chief Financial Officer | A | +84,750 deriv. | — |
| 2026-02-18 | Martha S. Rook | CHIEF OPERATING OFFICER | A | +84,750 deriv. | — |
| 2026-02-18 | Kevin Muir | GM INTERVENTIONAL ONCOLOGY | A | +84,750 deriv. | — |
| 2025-11-25 | John Richard Sylvester | Director | Buy | +4,386 | +$38.99K |
| 2025-11-13 | Gerard J Michel | CHIEF EXECUTIVE OFFICER | Buy | +11,500 | +$98.05K |
| 2025-06-13 | Vojo Vukovic | CHIEF MEDICAL OFFICER | M | +42,000 | +$200.76K |
| 2025-05-19 | John Richard Sylvester | Director | A | +22,500 deriv. | — |
| 2025-05-19 | Gil Aharon | Director | A | +22,500 deriv. | — |
| 2025-05-19 | Steven A J Salamon | Director | A | +22,500 deriv. | — |
| 2025-05-19 | Elizabeth Czerepak | Director | A | +22,500 deriv. | — |
| 2025-05-19 | Bridget A Martell | Director | A | +22,500 deriv. | — |
| 2025-05-09 | Gil Aharon | Director | X | +400,000 | +$4.00M |
| 2025-05-09 | Gil Aharon | Director | X | +1,200,000 | +$12.00M |
| 2025-05-09 | Steven A J Salamon | Director | X | +400,000 | +$4.00M |
| 2025-02-07 | Sandra Pennell | Chief Financial Officer | A | +113,000 deriv. | — |
| 2025-02-07 | Martha S. Rook | CHIEF OPERATING OFFICER | A | +113,000 deriv. | — |
| 2025-02-07 | Kevin Muir | GM INTERVENTIONAL ONCOLOGY | A | +113,000 deriv. | — |
| 2025-02-07 | Vojo Vukovic | CHIEF MEDICAL OFFICER | A | +113,000 deriv. | — |
| 2025-02-07 | Gerard J Michel | CHIEF EXECUTIVE OFFICER | A | +390,000 deriv. | — |
| 2025-02-07 | David L. Hoffman | GEN'L COUNSEL, CCO & SECY | A | +113,000 deriv. | — |
| 2024-12-27 | Steven A J Salamon | Director | C | +250,000 | +$2.50M |
| 2024-12-26 | Rosalind Advisors, Inc. | Director | C | +750,000 | +$7.50M |
| 2024-12-26 | Gil Aharon | Director | C | +250,000 | +$2.50M |
| 2024-11-01 | Gil Aharon | Director | MIXED | +500 deriv. | — |
| 2024-11-01 | Steven A J Salamon | Director | MIXED | +500 deriv. | — |
| 2024-11-01 | Gil Aharon | Director | MIXED | +1,500 deriv. | — |
| 2024-10-23 | Gerard J Michel | CHIEF EXECUTIVE OFFICER | M | +16,666 | +$100.00K |
| 2024-05-28 | Steven A J Salamon | Director | A | +22,500 deriv. | — |
| 2024-05-28 | Bridget A Martell | Director | A | +22,500 deriv. | — |
| 2024-05-28 | Gil Aharon | Director | A | +22,500 deriv. | — |
| 2024-05-28 | Elizabeth Czerepak | Director | A | +22,500 deriv. | — |
| 2024-05-28 | Roger G Phd Stoll | Director | MIXED | — | — |
| 2024-05-28 | John Richard Sylvester | Director | A | +22,500 deriv. | — |
| 2024-05-16 | Gil Aharon | Director | MIXED | +1,611,561 | +$6.20K |
| 2024-05-16 | Steven A J Salamon | Director | MIXED | +1,611,561 | +$3.84B |
| 2024-05-16 | Gil Aharon | Director | MIXED | +1,611,561 | +$3.84B |
| 2024-05-16 | Steven A J Salamon | Director | MIXED | +1,611,561 | +$6.20K |
| 2024-05-16 | Rosalind Advisors, Inc. | Director | MIXED | +4,834,683 | +$11.53B |
| 2024-05-16 | Rosalind Advisors, Inc. | Director | MIXED | +4,834,683 | +$18.60K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Steven A J Salamon | Director | 4,534,493 | $66.70M |
| Gil Aharon | Director | 4,483,178 | $65.95M |
| Rosalind Advisors, Inc. | Director | 3,417,095 | $50.27M |
| Gerard J Michel | CHIEF EXECUTIVE OFFICER | 342,034 | $5.03M |
| Vojo Vukovic | CHIEF MEDICAL OFFICER | 168,882 | $2.48M |
| Sandra Pennell | Chief Financial Officer | 77,018 | $1.13M |
| David L. Hoffman | GEN'L COUNSEL, CCO & SECY | 74,330 | $1.09M |
| Kevin Muir | GM INTERVENTIONAL ONCOLOGY | 18,582 | $273.34K |
| John Richard Sylvester | Director | 14,936 | $219.71K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DCTH quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.